Mostrar el registro sencillo del ítem
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
| dc.rights.license | open | en_US |
| dc.contributor.author | HUMBERT, M. | |
| dc.contributor.author | TAILLE, C. | |
| dc.contributor.author | MALA, L. | |
| dc.contributor.author | LE GROS, V. | |
| dc.contributor.author | JUST, J. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOLIMARD, Mathieu | |
| dc.date.accessioned | 2020-11-17T08:53:34Z | |
| dc.date.available | 2020-11-17T08:53:34Z | |
| dc.date.issued | 2018-05 | |
| dc.identifier.issn | 0903-1936 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/14051 | |
| dc.description.abstractEn | Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab.This retrospective real-life study was conducted in France between December 2015 and September 2016 using medical records of SAA omalizumab-treated patients. Response to omalizumab was assessed by three criteria: physician evaluation, reduction of >/=40% in annual exacerbation rate and a combination of both. Response rate was calculated according to blood eosinophil count measured in the year prior to omalizumab initiation.872 SAA omalizumab-treated patients were included by 78 physicians (723 adults (age >/=18 years) and 149 minors (age 6-17 years)). Blood eosinophil count was >/=300 cells.microL(-1) in 52.1% of adults and 73.8% of minors. By physician evaluation, 67.2% of adults and 77.2% of minors were responders and 71.1% adults and 78.5% minors had a >/=40% reduction in the exacerbation rate. In adults, the response rate for combined criteria was 58.4% (95% CI 53.2-63.4%) for blood eosinophils >/=300 cells.microL(-1) (n=377) and 58.1% (95% CI 52.7-63.4%) for blood eosinophils <300 cells.microL(-1) (n=346).This study shows that a large proportion of patients with SAA have a blood eosinophil count >/=300 cells.microL(-1), and suggests that omalizumab effectiveness is similar in "high" and "low" eosinophil subgroups. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject.en | PharmacoEpi-Drugs | |
| dc.title.en | Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study | |
| dc.title.alternative | Eur Respir J | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1183/13993003.02523-2017 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 29545284 | en_US |
| bordeaux.journal | The European respiratory journal | en_US |
| bordeaux.volume | 51 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 5 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The%20European%20respiratory%20journal&rft.date=2018-05&rft.volume=51&rft.issue=5&rft.eissn=0903-1936&rft.issn=0903-1936&rft.au=HUMBERT,%20M.&TAILLE,%20C.&MALA,%20L.&LE%20GROS,%20V.&JUST,%20J.&rft.genre=article |
